Newly FDA-Approved Revtorpyk™ (Gedatolisib) Included In The National Comprehensive Cancer Network® (Nccn®) Clinical Practice Guidelines For Hr+/Her2- Locally Advanced Or Metastatic Breast Cancer
CELC•Source note
Source text: ID:nGNX4NXtDJ
Further company coverage: CELC.O
FDA approval and launch timing
- Celcuity said the FDA approved Revtorpyk for HR+/HER2- advanced breast cancer without PIK3CA mutation on July 14, 2026.
- Celcuity said Revtorpyk is expected to be commercially available in the U.S. in late Q3 2026.
Guideline inclusion for Revtorpyk
- Newly FDA-approved Revtorpyk™ (gedatolisib) included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- locally advanced or metastatic breast cancer
